Development of Dengue Vaccine. Phase 2.
Abstract
Work has been in four areas: subcloning of NS1, characterization of anti-D3 human sera, subcloning of E, and expression of dengue proteins/peptides. Four HaeIII fragments subclones in lambda gtll have been identified in the correct orientation: Hae272, Hae166, Hae415 and Hae113. Alterations in the Western protocol have resulted in successful Western analysis with human sera. Several attempts to subclone various large fragments of the E gene into pSS20 have been unsuccessful. Lysogens of the complete NS1 gene and a truncated E have been generated and shown to produce the expected fusion proteins.
Document Details
- Document Type
- Technical Report
- Publication Date
- Dec 15, 1990
- Accession Number
- ADB160958
Entities
People
- John M. Ivy